Cellectis Sa Stock Performance
| CMVLF Stock | USD 5.04 0.78 18.31% |
Cellectis holds a performance score of 12 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.0801, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cellectis' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cellectis is expected to be smaller as well. Use Cellectis total risk alpha, as well as the relationship between the rate of daily change and period momentum indicator , to analyze future returns on Cellectis.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cellectis SA are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile essential indicators, Cellectis reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 241.1 M | |
| Total Cashflows From Investing Activities | 7.3 M |
Cellectis |
Cellectis Relative Risk vs. Return Landscape
If you would invest 258.00 in Cellectis SA on July 19, 2025 and sell it today you would earn a total of 246.00 from holding Cellectis SA or generate 95.35% return on investment over 90 days. Cellectis SA is currently producing 1.3717% returns and takes up 8.9883% volatility of returns over 90 trading days. Put another way, 80% of traded pink sheets are less volatile than Cellectis, and 73% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Cellectis Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cellectis' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Cellectis SA, and traders can use it to determine the average amount a Cellectis' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1526
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | CMVLF | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.99 actual daily | 80 80% of assets are less volatile |
Expected Return
| 1.37 actual daily | 27 73% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 12 88% of assets perform better |
Based on monthly moving average Cellectis is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cellectis by adding it to a well-diversified portfolio.
Cellectis Fundamentals Growth
Cellectis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Cellectis, and Cellectis fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cellectis Pink Sheet performance.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (6.01) % | |||
| Current Valuation | 82.79 M | |||
| Shares Outstanding | 55.59 M | |||
| Price To Earning | (13.64) X | |||
| Price To Book | 0.79 X | |||
| Price To Sales | 4.79 X | |||
| Revenue | 57.29 M | |||
| EBITDA | (103.2 M) | |||
| Cash And Equivalents | 153.13 M | |||
| Cash Per Share | 3.37 X | |||
| Total Debt | 18.77 M | |||
| Debt To Equity | 0.52 % | |||
| Book Value Per Share | 3.00 X | |||
| Cash Flow From Operations | (104.56 M) | |||
| Earnings Per Share | (2.95) X | |||
| Total Asset | 382.08 M | |||
| Retained Earnings | (206 M) | |||
| Current Asset | 297 M | |||
| Current Liabilities | 58 M | |||
About Cellectis Performance
By analyzing Cellectis' fundamental ratios, stakeholders can gain valuable insights into Cellectis' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cellectis has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cellectis has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis Romainvil operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 294 people.Things to note about Cellectis SA performance evaluation
Checking the ongoing alerts about Cellectis for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Cellectis SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cellectis SA is way too risky over 90 days horizon | |
| Cellectis SA appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 57.29 M. Net Loss for the year was (114.2 M) with profit before overhead, payroll, taxes, and interest of 34.18 M. | |
| Cellectis SA has accumulated about 153.13 M in cash with (104.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37. |
- Analyzing Cellectis' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cellectis' stock is overvalued or undervalued compared to its peers.
- Examining Cellectis' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cellectis' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cellectis' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cellectis' pink sheet. These opinions can provide insight into Cellectis' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cellectis Pink Sheet analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |